Latham & Watkins and Gowling WLG have taken roles on one of the biggest pharma deals of the year so far, as drug giants AstraZeneca and Daiichi Sankyo collaborate on a $6.9 billion cancer treatment.
The deal will see the global development and commercialisation of Japan-headquartered Daiichi Sankyo’s lead antibody drug, trastuzumab deruxtecan. It is designed to help treat a range of cancers including breast and gastric cancer, as well as non-small cell lung and colorectal cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
